Vivos Therapeutics (VVOS) Revenue (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Revenue for 7 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 34.9% year-over-year to $5.2 million in Q2 2026; TTM through Jun 2026 was $20.9 million, a 45.21% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, up 16.05% from the prior year.
• Revenue was $5.2 million for Q2 2026 at Vivos Therapeutics, roughly flat from $5.1 million in the prior quarter.
• Over five years, Revenue peaked at $6.8 million in Q3 2025 and troughed at $3.0 million in Q1 2025.
• A 5-year average of $4.0 million and a median of $3.8 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue slipped 22.26% in 2023 and jumped 75.73% in 2025, its largest moves.
• Over 5 years, Revenue stood at $4.0 million in 2022, then declined by 17.77% to $3.2 million in 2023, then grew by 13.85% to $3.7 million in 2024, then rose by 3.41% to $3.8 million in 2025, then soared by 34.75% to $5.2 million in 2026.
• The last three Revenue figures came in at $5.2 million (Q2 2026), $5.1 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.